D
XBiotech Inc. XBIT
$7.91 -$0.20-2.47%
Recommendation
Prev Close
Volume
Avg Vol (90D)
Market Cap
Dividend & Yield
--
52-Week Range
P/E (TTM)
--
EPS (TTM)
D
Sell 3/14/2024Upgraded
XBiotech Inc. (XBIT) was upgraded to D- from E+ on 3/14/2024 due to an increase in the volatility index and total return index.
E
Sell 2/28/2024Downgrade
XBiotech Inc. (XBIT) was downgraded to E+ from D- on 2/28/2024 due to a decline in the volatility index and valuation index.
D
Sell 2/8/2024Upgraded
XBiotech Inc. (XBIT) was upgraded to D- from E+ on 2/8/2024 due to an increase in the volatility index and total return index.
E
Sell 1/23/2024Downgrade
XBiotech Inc. (XBIT) was downgraded to E+ from D- on 1/23/2024 due to a decline in the volatility index and valuation index.
D
Sell 1/5/2024Upgraded
XBiotech Inc. (XBIT) was upgraded to D- from E+ on 1/5/2024 due to an increase in the volatility index.
E
Sell 12/21/2023Downgrade
XBiotech Inc. (XBIT) was downgraded to E+ from D- on 12/21/2023 due to a decline in the volatility index, total return index and valuation index.
D
Sell 12/6/2023Upgraded
XBiotech Inc. (XBIT) was upgraded to D- from E+ on 12/6/2023 due to an increase in the volatility index.
E
Sell 11/15/2023Downgrade
XBiotech Inc. (XBIT) was downgraded to E+ from D on 11/15/2023 due to a significant decline in the efficiency index, solvency index and volatility index. The quick ratio declined from 46.87 to 38.44, and total capital declined 2.8% from $229.06M to $222.66M.
D
Sell 6/16/2022Downgrade
XBiotech Inc. (XBIT) was downgraded to D from D+ on 6/16/2022 due to a decline in the total return index and volatility index.
D
Sell 6/1/2022Upgraded
XBiotech Inc. (XBIT) was upgraded to D+ from D on 6/1/2022 due to an increase in the volatility index and valuation index.
D
Sell 5/13/2022Downgrade
XBiotech Inc. (XBIT) was downgraded to D from D+ on 5/13/2022 due to a noticeable decline in the total return index, volatility index and growth index. Operating cash flow declined 191.25% from -$1.76M to -$5.12M, total revenue declined 88.89% from $4.5M to $500, and EBIT declined 9.05% from -$7.19M to -$7.85M.
D
Sell 2/16/2022Downgrade
XBiotech Inc. (XBIT) was downgraded to D+ from C- on 2/16/2022 due to a noticeable decline in the total return index and volatility index.
C
Hold 11/10/2021Upgraded
XBiotech Inc. (XBIT) was upgraded to C- from D+ on 11/10/2021 due to a major increase in the efficiency index. Net income increased 36.28% from -$5.12M to -$3.26M.
D
Sell 5/11/2021Upgraded
XBiotech Inc. (XBIT) was upgraded to D+ from D on 5/11/2021 due to a noticeable increase in the solvency index, efficiency index and growth index. Operating cash flow increased 562.66% from -$391 to $1.81M, the quick ratio increased from 62.26 to 90.01, and EBIT increased 27.81% from -$4.92M to -$3.55M.
D
Sell 4/16/2021Downgrade
XBiotech Inc. (XBIT) was downgraded to D from D+ on 4/16/2021 due to a decline in the total return index.
D
Sell 4/1/2021Upgraded
XBiotech Inc. (XBIT) was upgraded to D+ from D on 4/1/2021 due to an increase in the total return index and volatility index.
D
Sell 3/17/2021Downgrade
XBiotech Inc. (XBIT) was downgraded to D from C on 3/17/2021 due to a significant decline in the valuation index, growth index and total return index. Operating cash flow declined 105.23% from $7.48M to -$391, total revenue declined 50.05% from $10.55M to $5.27M, and EBIT declined 5.4% from -$4.67M to -$4.92M.
C
Hold 12/18/2020Downgrade
XBiotech Inc. (XBIT) was downgraded to C from C+ on 12/18/2020 due to a major decline in the total return index.
C
Hold 11/10/2020Upgraded
XBiotech Inc. (XBIT) was upgraded to C+ from C- on 11/10/2020 due to a significant increase in the growth index, total return index and solvency index. Operating cash flow increased 164.69% from -$11.57M to $7.48M, the quick ratio increased from 18.06 to 40.43, and earnings per share increased from -$0.2372 to -$0.09.
C
Hold 9/11/2020Downgrade
XBiotech Inc. (XBIT) was downgraded to C- from C on 9/11/2020 due to a decline in the volatility index.
C
Hold 8/24/2020Upgraded
XBiotech Inc. (XBIT) was upgraded to C from C- on 8/24/2020 due to a substantial increase in the total return index, efficiency index and solvency index.
C
Hold 7/29/2020Upgraded
XBiotech Inc. (XBIT) was upgraded to C- from D+ on 7/29/2020 due to a noticeable increase in the total return index and volatility index.
D
Sell 5/20/2020Downgrade
XBiotech Inc. (XBIT) was downgraded to D+ from C- on 5/20/2020 due to a major decline in the total return index, growth index and volatility index. Operating cash flow declined 1,519.67% from -$3.75M to -$60.67M, and earnings per share declined from $9.7123 to -$0.0004.
C
Hold 3/18/2020Upgraded
XBiotech Inc. (XBIT) was upgraded to C- from D on 3/18/2020 due to a significant increase in the valuation index, efficiency index and total return index. Net income increased 11,262.52% from -$6.15M to $686.5M, and total capital increased 1,069.31% from $64.62M to $755.63M.
D
Sell 8/13/2019Upgraded
XBiotech Inc. (XBIT) was upgraded to D from D- on 8/13/2019 due to a major increase in the growth index, total return index and volatility index. Earnings per share increased from -$0.163 to -$0.156.
D
Sell 5/31/2016Upgraded
XBiotech, Inc. (XBIT) was upgraded to D- from E+ on 5/31/2016 due to an increase in the total return index and volatility index.
E
Sell 5/13/2016Downgrade
XBiotech, Inc. (XBIT) was downgraded to E+ from D- on 5/13/2016 due to a decline in the efficiency index and valuation index. Total capital declined 8.12% from $103.05M to $94.68M.
D
Sell 5/5/2016Upgraded
XBiotech, Inc. (XBIT) was upgraded to D- from E+ on 5/5/2016 due to an increase in the volatility index and total return index.
E
Sell 4/20/2016Downgrade
XBiotech, Inc. (XBIT) was downgraded to E+ from D- on 4/20/2016 due to a decline in the valuation index, volatility index and total return index.
D
Sell 3/31/2016Upgraded
XBiotech, Inc. (XBIT) was upgraded to D- from E+ on 3/31/2016 due to an increase in the efficiency index, growth index and volatility index.
E
Sell 3/11/2016Downgrade
XBiotech, Inc. (XBIT) was downgraded to E+ from D- on 3/11/2016 due to a large decline in the volatility index and total return index.
D
Sell 1/4/2016Upgraded
XBiotech, Inc. (XBIT) was upgraded to D- from E+ on 1/4/2016 due to an increase in the valuation index.
E
Sell 10/1/2015Upgraded
XBiotech, Inc. (XBIT) was upgraded to E+ from E on 10/1/2015 due to an increase in the valuation index.
E
Sell 9/28/2015Upgraded
XBiotech, Inc. (XBIT) was upgraded to E from E- on 9/28/2015 due to an increase in the valuation index.
E
Sell 8/31/2015Downgrade
XBiotech, Inc. (XBIT) was downgraded to E- from E on 8/31/2015 due to a decline in the valuation index and total return index.
E
Sell 8/14/2015Upgraded
XBiotech, Inc. (XBIT) was upgraded to E from E- on 8/14/2015 due to an increase in the total return index, growth index and valuation index. Operating cash flow increased 35.71% from -$6.53M to -$8.86M.
E
Sell 7/10/2015None
XBiotech Inc. (XBIT) was downgraded to E- from U on 07/10/2015.
Weiss Ratings